Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Nanotherapeutics and the Vaccine Branch of the National Cancer Institute Enter Into Cooperative Research and Development Agreement (CRADA)

Abstract:
Nanotherapeutics, Inc. announced today that it has entered into a two year Cooperative Research and Development Agreement (CRADA) with the Vaccine Branch of the National Cancer Institute (NCI) to produce HIV peptide oral vaccine nanoparticles using the company's proprietary technology. The collaboration with NCI will employ the company's nanoparticle delivery system, which enables oral targeted delivery of macromolecules such as peptides, to facilitate oral delivery in the GI tract to improve immune response.

Nanotherapeutics and the Vaccine Branch of the National Cancer Institute Enter Into Cooperative Research and Development Agreement (CRADA)

ALACHUA, FL | Posted on August 7th, 2007

James D. Talton, Ph.D., President of Nanotherapeutics and co-founder of the company, is the company's principal investigator on the project. Dr. Talton said, "The CRADA marks a significant milestone for the company and an important step in the development of novel HIV vaccines. When the NCI came to us to request our help in their HIV oral vaccine project, naturally, we were excited that our technology was recognized by them and that the Vaccine Branch had chosen to collaborate with us in this vital area of HIV research and development."

Also commenting on the CRADA, Mento A. "Chuck" Soponis, Chairman and CEO of Nanotherapeutics said, "This recognition is further validation of the work Dr. Talton and our scientists have been conducting over the past several years in the area of stabilized particle-based vaccine delivery. Entering into this collaborative relationship with the NCI's Vaccine Branch, demonstrates both the scientific and competitive strength of Nanotherapeutics."

In 2005, Nanotherapeutics received funding from National Institute on Drug Abuse (NIDA) to develop an oral nanoparticle medication to treat opiate addiction. The company also received funding from the National Institute of Allergy and Infectious Diseases (NIAID), as part of the National Institutes of Health (NIH) research program on Medical Countermeasures against Radiological and Nuclear Threats, to improve the delivery of an injectable treatment, and from Project Bioshield.

####

About Nanotherapeutics, Inc.
Nanotherapeutics Inc., an emerging specialty pharmaceutical company with expertise in the early-stage development of pharmaceuticals, is a privately held corporation located in Florida. The company is a provider of specialized drug delivery systems that use the company’s discoveries in nanotechnology to develop novel drug therapies or improved formulations for existing therapies. The company employs several platform technologies to manipulate and enhance the properties of drugs. These technologies can be employed with new chemical entities or with generic drugs and can be used with the spectrum of existing drug types ranging from small synthetic molecules to large recombinant macromolecules.

Significant advances have been made in the area of nanometer-scale particle delivery and Nanotherapeutics has created three proprietary drug delivery technologies: NanoQUAD™, NanoDRY™, and NanoCOAT™. These specialized proprietary techniques can improve the release rate and enhance both the rate and extent of drug uptake, thus increasing bioavailability. The consequences of these changes include more consistent drug therapy with potentially reduced dose and dose frequency requirements and fewer side effects.

For more information, please click here

Contacts:
Nanotherapeutics
Chuck Soponis
386-462-9663
Chairman & CEO

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Novel nanoparticle therapy promotes wound healing March 27th, 2015

Graphene reduces wear of alumina ceramic March 26th, 2015

Application of Graphene Oxide in Body Implants in Iran March 26th, 2015

Nanorobotic agents open the blood-brain barrier, offering hope for new brain treatments March 25th, 2015

Announcements

Nanoscale worms provide new route to nano-necklace structures March 29th, 2015

Solving molybdenum disulfide's 'thin' problem: Research team increases material's light emission by twelve times March 29th, 2015

A first glimpse inside a macroscopic quantum state March 28th, 2015

DFG to Establish One Clinical Research Unit and Five Research Units: New Projects to Investigate Complications in Pregnancy, Particle Physics, Nanoparticles, Implants and Transport Planning / Approximately 13 Million Euros in Funding for an Initial Three-Year Period March 28th, 2015

Research partnerships

SUNY Poly & M+W Make Major Announcement: Major Expansion To Include M+W Owned Gehrlicher Solar America Corporation That Will Create up to 400 Jobs to Develop Solar Power Plants at SUNY Poly Sites Across New York State March 26th, 2015

ORNL-led team demonstrates desalination with nanoporous graphene membrane March 25th, 2015

New kind of 'tandem' solar cell developed: Researchers combine 2 types of photovoltaic material to make a cell that harnesses more sunlight March 24th, 2015

UW scientists build a nanolaser using a single atomic sheet March 24th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE